BMJ Open

Acute pain pathways: protocol for a prospective cohort study

Molly Moore Jeffery, Mitra Ahadpour, Summer Allen, Richardae Araojo, Fernanda Bellolio, Nancy Chang, Laura Ciaccio, Lindsay Emanuel, Jonathan Fillmore, Gregg H Gilbert, Patricia Koussis, Christine Lee, Heather Lipkind, Celeste Mallama, Tamra Meyer, Megan Moncur, Teryl Nuckols, Michael A Pacanowski, David B Page, Elektra Papadopoulos, Jessica D Ritchie, Joseph S Ross, Nilay D Shah, Mat Soukup, Christopher O St. Clair, Stephen Tamang, Sam Torbati, Douglas W Wallace, Yueqin Zhao, Laura Ciaccio, Lindsay Emanuel, Matthew Serrador, Nancy Chang, Laura Ciaccio, and Megan Moncur.

ABSTRACT

Introduction Opioid analgesics are often used to treat moderate-to-severe acute non-cancer pain; however, there is little high-quality evidence to guide clinician prescribing. An essential element to developing evidence-based guidelines is a better understanding of pain management and pain control among individuals experiencing acute pain for various common diagnoses.

Methods and analysis This multicentre prospective observational study will recruit 1550 opioid-naive participants with acute pain seen in diverse clinical settings including primary/urgent care, emergency departments and dental clinics. Participants will be followed for 6 months with the aid of a patient-centred health data aggregating platform that consolidates data from study questionnaires, electronic health record data on healthcare services received, prescription fill data from pharmacies, and activity and sleep data from a Fitbit activity tracker. Participants will be enrolled to represent diverse races and ethnicities and pain conditions, as well as geographical diversity. Data analysis will focus on assessing patients’ patterns of pain and opioid analgesic use, along with other pain treatments; associations between patient and condition characteristics and patient-centred outcomes including resolution of pain, satisfaction with care and long-term use of opioid analgesics; and descriptive analyses of patient management of leftover opioids.

Ethics and dissemination This study has received approval from IRBs at each site. Results will be made available to participants, funders, the research community and the public.

Trial registration number NCT04509115.

INTRODUCTION

Opioid analgesics are often used to treat moderate-to-severe acute non-cancer pain; however, there is little high-quality evidence to guide clinician prescribing. A recent high quality systematic review of the comparative effectiveness of treatments for acute pain found substantial limitations in the strength of evidence on basic questions of comparative effectiveness of opioids versus both pharmacological and non-pharmacological treatments. None of the primary pharmacological treatments for acute pain—opioids, non-steroidal anti-inflammatory drugs and acetaminophen—were found to be superior to the others across the range of acute pain conditions, and the evidence did not address whether treatment effectiveness may vary across patient populations. Opioid prescribing in the USA has been declining over the past 10 years, but remains common. Substantial variation in opioid prescription characteristics (eg, number of pills prescribed) for similar patients has been

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This study addresses a key knowledge gap by recruiting a large and diverse group of patients with acute pain, following them for 6 months, and prospectively assessing their pain experience and acute pain treatment.

⇒ Patients will be recruited from multiple treatment settings that are important in the treatment of acute pain, including emergency departments, primary care, dental settings and surgical settings.

⇒ A patient-centred health data aggregating platform reduces the patient burden of participating in the trial by allowing participants to complete questionnaires when it is convenient and by automatically collecting data on physical activity, healthcare service use and prescription fills.

⇒ All participants will have been offered an opioid prescription, reducing the ability to compare outcomes across opioid and non-opioid pain medications.

⇒ Despite a large sample size, there may be limited numbers of specific acute pain diagnoses with a sufficient sample to analyse and compare by condition/diagnosis.
observed and may indicate a lack of consensus about the ideal dose and duration of treatment for various types of common painful ailments. Many studies report the efficacy of opioids for acute pain, but few address the ideal dose and duration of treatment for various types of pain. Among the many clinical guidelines that recommend a specific duration of treatment or number of pills, most rely on expert consensus in the absence of higher quality evidence. Appropriate opioid prescribing for acute pain must balance both potential benefits and risks to patients and broader risks to public health.

Current knowledge
There is no consensus on the definition of acute pain; one definition is pain that is time limited and of sudden onset. Acute pain is often treated differently depending on the practice setting in which patients find themselves and the specific providers from whom they receive care. For example, a recent study of postsurgical pain conducted at Mayo Clinic demonstrated substantial variation across surgeons in the amount of opioids prescribed (measured in milligram morphine equivalents (MMEs)) which could not be explained by patient factors for 25 of the most common surgical procedures. This finding was replicated using national data from insurance claims. The large observed variability across surgeons in opioid volume prescribed, even after accounting for patient characteristics, suggests that clinicians lack evidence-based guidance on opioid prescribing for postsurgical pain. A recent systematic review found that studies of postsurgery opioid prescribing commonly reported 50%–70% of prescribed opioid tablets were left unused. These unconsumed opioids suggest overprescribing and pose a potential risk to patients and the community if the opioids are diverted for non-medical use.

Data are limited with regard to the experience of acute pain, rates of opioid prescribing, clinical outcomes, alignment with recommendations and disparities in care, particularly outside of surgical care, such as emergency departments (EDs), primary care/urgent care settings and dental and oral surgery centres.

Emergency department
An analysis of the Medical Expenditure Panel Survey from 1996 to 2012 indicated that overall opioid prescribing increased 471% during that time but that the contribution of prescriptions from EDs decreased from 7.4% to 4.4%. While more recent data demonstrate a high level of adherence to recommended guidelines for prescribing of opioids in the ED, there is still limited evidence around the best approaches for pain control and opioid use after initial prescription in the ED. Additionally, the guideline recommendations for dose and duration of treatment are largely based on expert opinion and lower-quality evidence. Furthermore, a recent meta-analysis and systematic review found that Black and Hispanic patients in US EDs were less likely to receive treatment for acute pain than their White counterparts; few studies assessed data for Asian and Native American patients, making the estimates less robust, but the data suggested there may be similar disparities.

Primary care/urgent care
Although primary care providers may treat a larger proportion of patients with chronic pain than their surgical or emergency medicine colleagues, providers in primary care and urgent care settings still treat a diverse array of conditions associated with acute pain, including headaches, dental pain and musculoskeletal injuries. Preliminary studies have suggested that prescriptions for 7 or fewer days of opioid medications are adequate for most patients seen in primary care. However, a study of primary care visits for common acute pain conditions found that 46% of the opioid prescriptions filled after these visits were for more than 7 days’ supply, and 10% were for 30 or more days’ supply. Additionally, when US primary care providers prescribe opioids, they are the most common type of provider to provide a long-term prescription, with 40% of these initial prescriptions exceeding a 7-day supply.

Dental care and oral surgery
A recent study comparing opioid prescribing by dentists practicing in the USA and UK found that US dentists were much more likely to prescribe opioids than UK dentists (58.2 opioid prescriptions per US dentist per year vs 1.2 opioid prescriptions per UK dentist per year). This large difference may indicate that US dentists are over prescribing opioids, but without additional detail on patients’ use and disposal of their dental opioid prescriptions, we cannot determine what harms may be associated with this presumed over-prescription. Despite this comparatively high rate of opioid prescribing by US-based dentists, dentists are less likely to prescribe long courses of opioids when compared with other types of prescribing providers in the USA.

Opioid prescribing to adolescents may be associated with an increased risk of later substance use disorders and overdoses. For example, a population-based study in Sweden found a 30%–40% relative increase in a composite measure of substance-related morbidity compared with matched cohorts not receiving an opioid. In the USA, dentists were the most common prescribers of opioids for people aged 0–21 years, writing 38.2% of these prescriptions. Among adolescents and young adults (age 12–25), tooth extractions were by far the most common procedure associated with a new dental opioid prescription (79.4%).

It is not known whether dental prescribing is likely to progress to long-term opioid use or whether unused opioids from dental prescribing are likely to be retained.

Study aims
The purpose of this study is to as certain and describe the trajectories of pain experienced by diverse group of opioid naïve patients who are prescribed an opioid
analgesic for acute pain. Using a digital health-based patient-centred data aggregation platform, we aim to characterise patterns of use of opioids and other pain medications. We aim to enrol a total of 1550 patients receiving primary and urgent care, ED care, oral/dental care in five healthcare systems, along with several community dental practices. Opioid naive patients offered a new short-acting opioid prescription for acute pain will be recruited and followed prospectively for 6 months to assess pain trajectories, analgesic and non-pharmacological treatment use, activity and healthcare service use. A patient-centred health data aggregating platform (Hugo Health; further information below) will be used to collect patient-reported outcomes and structured data from pharmacy and electronic health record (EHR) patient portals as well as patient-generated data collected through personal activity tracking devices (Fitbit).

There are three study aims:
1. To assess patients’ pain and opioid use patterns in episodes of acute pain for which opioids were prescribed, tracking pain severity and persistence, as well as other prescription and over-the-counter pain medication use.
2. To examine associations between patient demographic, clinical and emotional characteristics and outcomes of pain severity and persistence, opioid and non-opioid treatment patterns, satisfaction with care and barriers to care.
3. To assess how patients handled unused opioids both during and at the end of treatment (i.e., leftovers).

A primary goal for the study is to include populations not currently well-represented in the body of evidence on opioids and acute pain, including people from under-represented racial and ethnic groups and people living in rural areas.

**METHODS**

This is a prospective cohort study using a novel, patient-centred electronic health data aggregating platform to follow study participants for 180 days, gathering rich data on the course of acute pain, how people treat their pain, and how this acute pain affects their social and emotional functioning.

Opioid naive patients offered an opioid prescription for acute pain will be recruited at the point of care where the prescription was written. The population will be a convenience sample of patients who are either present in the care setting when a study coordinator is available to recruit in person or who are reachable by telephone for recruitment after their visit. They will be followed for 180 days, during which they will use their personal smartphone or other web-connected device to answer questionnaires that track the location, severity and daily consequences of their pain; treatments they are using to manage their pain; treatment effectiveness; mood and potential indicators of problematic opioid use. Structured information from EHR and pharmacy patient portals will be collected to record prescriptions that were written and filled, healthcare service use, and healthcare service-related outcomes (e.g., ED visits).

The study will be based at five primary investigative sites in the USA (figure 1): Yale University (Connecticut), Mayo Clinic (Minnesota), University of Alabama at Birmingham, Monument Health (South Dakota), and Cedars-Sinai Medical Center (Southern California). Participants will be recruited at both community and academic hospitals and clinics associated with these sites, along with community dental practices in several southeastern states along the southern Appalachian Mountains (enrollment coordinated through University of Alabama at Birmingham).

---

**Acute Pain Pathways study**

**Healthcare center near Air force base and American Indian reservations**
- 12% American Indian/Alaska Native*
- Busiest ED in SD

**Urban, high poverty**
- 27% African American*
- 15% Hispanic/Latino*
- 30-40% below 100% FPL*

**Rural ED and primary care**
- 5 EDs and >40 primary care practices in MN and WI
- Sites include college towns, agricultural, and food processing industries

**Community dental practices**
- Dental care in community practices across the South
- >80% African American*

**Academic dental practice**
- 80% age 15-24* (impacted wisdom teeth)

**Urban post-industrial**
- 21% Hispanic/Latino*
- 90% African American*
- <3% low English proficiency*
- Very high opioid OD death rate*

**Urban South**
- 43% African American*
- High opioid Ix rate*

**ED serving older population**
- 43% age >65

* Demographic refers to study participants
* Demographic refers to hospital population

---

**Figure 1** Study sites.
Recruitment will stop when approximately 1550 subjects have been enrolled. Enrolment targets (table 1) are stratified by study site and care setting (ED, primary and urgent care, and dental care), with overall demographic targets to ensure the study population is diverse in both racial and ethnic representation and rural/urban residence. Rural dwelling will be determined using participant home ZIP code. Race and ethnicity will be determined by participant self-report, offering the opportunity for participants to select multiple races. People who self-define as part of a racial or ethnic minority and as white will be classified by their non-white race or ethnicity for purposes of counting enrolment quotas.

People aged 15–17 receiving third molar extraction will be eligible for recruitment at the Mayo Clinic site in Rochester to allow a focused analysis of the pain experience and opioid use of this important and understudied population.

### Inclusion criteria

1. Age 18 and over; or age 15 and over undergoing third molar extraction at Mayo Clinic in Rochester.
2. English-speaking.
3. Experiencing an acute pain condition of less than 8 weeks duration at the time opioids are offered.
4. Offered prescription for opioid analgesic to treat acute pain.
5. Opioid naive (no use of prescribed opioids or illicit opioids, including medical or non-medical use, in the past 6 months) by self-report.
6. Willing and able to give consent and participate in study.
7. Able to access a mobile device (smartphone or tablet) or computer with web access to complete study questionnaires; able to connect Fit bit to a device that can regularly link to Hugo for data transfer.
8. Willing to use the health data aggregating platform.
9. Released/discharged to home after their visit.

### Exclusion criteria

1. Pain thought by treating clinician to be caused by a systemic disease very likely to progress to chronic pain (eg, sickle cell disease, fibromyalgia, lupus, multiple sclerosis).
2. Cancer or end-of-life related pain.
3. Unable to give consent and be enrolled within 3 days of being offered the prescription.

It is a limitation of the study that we are not able to provide smartphones or tablets to participants who do not have one. However, smartphone adoption is high at 85% of American adults, including 76% of those with income below $30,000 and 80% of those living in rural areas, and with minimal gaps by race and ethnicity.23

### Measures and data collection

Overview of electronic health data aggregating technology: Hugo is a patient-centred health data aggregating platform developed to foster partnership between research study/clinical trial participants and investigators. Hugo currently enables the secure, automatic and ongoing deposit of three types of data: clinical data via retrieval from patient portals; patient-generated data with support for a growing number of wearable/medical devices; and patient-reported data via a flexible survey feature. Hugo survey links can be delivered directly to users by email or text enabling the collection of encrypted responses for a wide range of questions including validated patient-reported outcome measures. Proprietary software harmonises data from different sources, aligning data types and eliminating duplicate information. By leveraging each person’s right to access his or her own data, Hugo’s patient portal-based approach solves patient identity matching issues and removes the need for data sharing agreements with health systems and institutions.

Questionnaires will be sent by Hugo to patients at varying intervals throughout the follow-up period, with the specific questions and frequency dependent on patient-reported pain and opioid use (table 2).

- All patients will receive:
  - An enrolment questionnaire to complete during the enrolment process.
  - A baseline questionnaire to be completed at home.
  - A closeout questionnaire sent at the end of the 6-month follow-up period.

- While patients report pain (including pain that is not related to their initial visit), they will receive:
  - Short daily questionnaires.
  - Weekly questionnaires.
  - Monthly questionnaires.

- When patients are not in pain, they will receive:

<table>
<thead>
<tr>
<th>Table 1 Planned patient enrolment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mayo Clinic</strong></td>
</tr>
<tr>
<td>-----------------</td>
</tr>
<tr>
<td>Emergency department</td>
</tr>
<tr>
<td>Primary and urgent care</td>
</tr>
<tr>
<td>Dental</td>
</tr>
<tr>
<td><strong>Total</strong></td>
</tr>
</tbody>
</table>

Overall demographic goals: 20%+ racial or ethnic minorities. 20%+ rural.
When patients report in their daily questionnaires that pain is resolved (for 3 days in a row the patient reports an overall pain rating of 0), the daily questionnaires will be stopped, and patients will instead only receive weekly and monthly questionnaires. Two sets of weekly and monthly questionnaires are available; one for those actively reporting pain and one for those not reporting pain. The appropriate questionnaires will be sent to patients based on their response to previous questionnaires. Should they begin reporting pain again in a weekly questionnaire, the ‘in pain’ questionnaire schedule will resume until they again report they have stopped experiencing pain, or until the follow-up period ends.

Two weeks after patients report that they have stopped taking an opioid to treat their pain, they will receive an additional questionnaire that will examine reasons for opioid discontinuation, pain treatment satisfaction, medication disposal and whether they experienced any potential indicators of medication misuse. Patients continuing opioid use through the end of the follow-up period will be asked the questions on pain treatment satisfaction and medication misuse at the end of the follow-up period.

Using the Hugo platform, we will collect data from electronic medical records from each participating system, all other locations where patients receive care, and from pharmacy portals (Walgreens, CVS and Walmart) related to medication fills (table 3). Together, this will allow us to capture information on comorbidities, opioid

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Content of study questionnaires</th>
</tr>
</thead>
<tbody>
<tr>
<td>Questionnaire</td>
<td>Patient reported outcome question sources (no of questions included)</td>
</tr>
<tr>
<td>Daily (While in pain, including pain not related to initial visit)</td>
<td>► Brief Pain Inventory27 (3) ► Collaborator suggested questions (4)</td>
</tr>
<tr>
<td>Weekly (While in pain, including pain not related to initial visit)</td>
<td>► PROMIS-29 Profile V.2.128 (25) ► Study of parents using opioids28 (2) ► Collaborator suggested questions (7)</td>
</tr>
<tr>
<td>Monthly (While in pain, including pain not related to initial visit)</td>
<td>► Prescribed Opioids Difficulties Scale29 (11) ► Collaborator suggested questions (1)</td>
</tr>
<tr>
<td>Weekly (Not in pain)</td>
<td>► Brief Pain Inventory27 (3) ► Collaborator suggested questions (8)</td>
</tr>
<tr>
<td>Monthly (Not in pain)</td>
<td>► PROMIS–29 Profile V.2.128 (29) ► Study of parents using opioids28 (2) ► Collaborator suggested questions (2)</td>
</tr>
<tr>
<td>Two weeks post opioid discontinuation</td>
<td>► KFF/Washington Post survey30 (18) ► University of South Florida and Purdue Pharma study of disposal31 (3) ► Washington University disposal survey25 (3) ► PROMIS Prescription Pain Medication Misuse33 (6) ► Collaborator suggested questions (2)</td>
</tr>
<tr>
<td>Beginning of study questionnaires (Enrolment and baseline)</td>
<td>► Demographics (7) ► KFF/Washington Post survey30 (12) ► National Association of Community Health Centres; Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences34 (15) ► National Health Interview Survey35 (49) ► PROMIS–29 Profile V.2.128 (25) ► University of South Florida and Purdue Pharma study of disposal31 (2) ► Tobacco, Alcohol, Prescription medications and other Substance36 (maximum 30) ► Pain Medication Beliefs Questionnaire37 (5) ► Collaborator suggested questions (19)</td>
</tr>
</tbody>
</table>
Comparison of directions for use and actual use: for use of non-opioids and non-opioid analgesics prescribed, and prescription opioids and non-opioid analgesics dispensed.

**Analysis plan**

An important goal of this project is to develop evidence to support condition-specific prescribing guidelines that address common acute pain conditions for which opioids are prescribed.

**Primary analyses**

The primary statistical analyses will be descriptive analyses of the outcomes derived from patient questionnaires describing the acute opioid analgesic use of participants. Each outcome will be summarised across care setting populations (ie, primary care, dental care, ED) and also stratified by race and ethnicity, rurality, gender, age group and opioid indication/patient condition.

Specific aim 1: To assess patients’ pain and opioid use patterns in episodes of acute pain for which opioids were prescribed, tracking pain severity and persistence, as well as other prescription and over-the-counter pain medication use.

- Distribution of initial opioid prescription and subsequent dispensings: drug type, strength, number of pills dispensed and directions for use.
- Use of non-opioid drugs/treatments: drug or treatment, number of days used, number of days used on which opioids were also used (ie, overlap with opioid treatment).
- Comparison of directions for use and actual use: for each day the person takes opioids, measure whether the number of pills taken falls within the range prescribed, below the prescribed range or above the prescribed range.
- Time to opioid discontinuation: defined as 30 days with no opioid use. The time to discontinuation will be counted from initial opioid use to the day on which the last opioid was taken. If 30 days pass with no opioid use, but the participant takes an opioid on the 31st day, a new episode of opioid use will be considered to have started and the time to opioid discontinuation will again be assessed.

- Time to pain resolution (defined as patient no longer indicating pain in the body area initially treated).
- Number of opioid dispensings and total amount of opioids dispensed (in MME).
- Average steps per day registered by Fitbit and trajectory over time (decreasing, increasing, stable) for the periods between enrolment and stopping opioids, enrolment and pain resolution.

Specific aim 2: To examine associations between patient demographic, clinical and emotional characteristics and outcomes of pain severity and persistence, opioid and non-opioid treatment patterns, satisfaction with care and barriers to care.

- Reported satisfaction with healthcare received to treat pain.
- Reported barriers to accessing additional treatment: proportion reporting difficulty getting a refill, getting a pharmacy to fill, getting insurance to pay for treatment, being able to afford to pay for treatment.
- Progression to long-term use of opioids.
- Progression to chronic pain.
- Possible misuse of opioids (per cent reporting use of opioids for purpose other than pain relief, per cent reporting use of opioids for longer than directed or using more than directed, per cent using opioids not prescribed for them, etc); proportion reporting each indicator.

Specific aim 3: To assess how patients handled unused opioids both during and at the end of treatment (ie, leftovers).

- Received healthcare provider or pharmacist instructions on disposal: proportion reporting receiving information on how to properly dispose of medication,
receiving information on the importance of disposing of unused medication.

- Opioids left over after opioid discontinuation and estimated amount used during study period (measured in absolute amounts—e.g., mg of oxycodone—as well as MME and tablets).
- Method of storage used
- Method of disposal used.
- Motivations for disposing of or keeping leftover drugs (proportion reporting each response (see questionnaire for responses).

Secondary analyses

Secondary analyses will assess the association between patient characteristics and outcomes using statistical modelling and will be exploratory in nature.

Patient characteristics that will be included in the analyses:

- Clinical comorbidities, including other chronic and acute painful conditions, as reported by the participant in the beginning of study questionnaire.
- Patient age and other demographics
- Substance use.
- Pain severity ratings (average from first week of follow-up; time-varying covariate).
- Pain interference.
- Treatment effectiveness (ie, did the patient report that opioids were effective).
- State of residence.

Data collection and management

The Hugo platform will collect all information available in the EHRs, pharmacy records, and through the wearable devices and questionnaires. No data will be collected by investigators directly from the health systems at which patients are receiving care. All linked health portals are password-protected and all account links are verified by the study participant on set up. Patients authenticate themselves through the use of their unique device account username and password.

The data will reside within the Hugo cloud-based platform and will be transferred to Mayo Clinic via a secure file transfer service. The data will then reside on secure servers at Mayo Clinic. The analytical data files stored at Mayo Clinic will not be deidentified but will be treated as a limited data set where patient identifiers are stored in a separate linkable file. The analytical data files will have other protected health information such as dates of service, etc and will be used for enrolment, troubleshooting and data monitoring.

The data collected as part of this project will not be part of the medical record and will not be provided back to the clinical care team. Patients will be made aware of this as part of the informed consent process and will be asked to contact the care team directly if they have any concerns related to their health.

Data will be stored at Mayo Clinic for 5 years after the end of the study. At the end of the 5 years, data will be archived in secure storage at Mayo Clinic similar to clinical trial and other prospectively collected data.

Deidentified data will be stored at the Food and Drug Administration (FDA) indefinitely for sharing both with internal investigators as well as external researchers. The informed consent will be explicit in that participants are agreeing for their deidentified data to be used by external groups for research or regulatory purposes.

Confidentiality

All data and records generated during this study will be kept confidential in accordance with Institutional policies and federal regulations including the Health Insurance Portability and Accountability Act (HIPAA) on subject privacy.

Data quality monitoring

The research staff will regularly monitor the status of the portal data (EHR/pharmacy/Fitbit) coming into the Hugo platform using the version of the Hugo dashboard only available to research staff. Within this dashboard, the research staff will be able to review the connection status of all of the portals connected to each patient’s Hugo account. Should a connectivity issue be noticed by research staff, they will note the connection issue reported by the dashboard and determine if the issue is limited to one participant or if multiple participants are experiencing the same problem. The research staff will then follow-up directly with the Hugo support team. Once the source of the issue is identified, the research staff will follow-up with the affected patients as needed to correct the issue in a timely fashion.

Research staff will also keep track of any technical issues directly reported by patients during their follow-up period. If the technical issues are not able to be resolved by the research staff, or if multiple patients report the same problem, the research staff will forward the issue to the Hugo support team to identify and correct the issue and in order to follow-up with those patients affected.

The study was selected to receive quality monitoring oversight using the FDA Office of Translational Sciences Quality Management System (QMS) for human subject research conducted or supported by the FDA. The QMS involves the use of standard operating procedures, checklists and templates when conducting quality assurance monitoring activities including site visits. In 2020, four virtual pre-enrolment visits (due to COVID-19 restrictions) were completed as well as one onsite interim visit in 2021 and three virtual interim visits in 2022. Individuals contracted to monitor the study on behalf of the FDA may access personal information collected as part of this study, including all of the information shared with the research team from the patients’ Hugo account. Monitoring activities are done to ensure adequate projection of the rights, welfare and safety of human subjects and the quality of the clinical trial data. These individuals are all obligated to maintain confidentiality by the nature of their work or are bound by confidentiality agreements.
Open access

Statistical methods
Baseline data
Baseline and demographic characteristics will be summarised by standard descriptive summaries (eg, means and SD for continuous variables such as age and percentages for categorical variables such as race and ethnicity, medians and quartiles for skewed data).

Primary analyses
The primary analyses will include all subjects. Tables will be presented with percentages, means and SEs, medians and 25th, 75th and 90th percentiles, and minimums and maximums, as appropriate.

Secondary analyses
Secondary analyses will be exploratory and use statistical modelling to estimate the association between patient characteristics and outcomes. Survival analysis techniques will be used to analyse time to event outcomes. Negative binomial regression will be used to analyse count outcomes (opioids leftover, number of refills).

Missing data
Multiple imputation will be used to handle missing outcome and covariate data in these analyses. Chained equations will be used to impute each variable with missing data.24 25 The number of imputations used will be 20 or more for each analysis. Sensitivity analyses will be conducted using missing categories for covariates and including only people with non-missing outcome information.

Sample size and statistical significance
This study is designed to gather information rather than to detect statistically significant differences between populations. For that reason, we did not provide a sample size analysis.

Patient and public involvement
A patient advisory group gave input on the design of the study and the patient-reported outcome survey items and schedule. The development of the research question was informed by research on patient priorities and preferences, but no patients were directly involved in forming the research question. Patients were not involved in the recruitment to and conduct of the study. Study participants will not be directly contacted to disseminate study results, though results will be made public through scientific publications and press engagement.

Study limitations
All participants will have been offered an opioid prescription, reducing the ability to compare outcomes across opioid and non-opioid pain medications. Despite a large sample size, there may be limited numbers of specific acute pain diagnoses with a sufficient sample to analyse and compare by condition/diagnosis. We are unable to offer patients a tablet or phone if they do not have one, which may limit participation. Finally, we are limited to recruiting a convenience sample of patients who present for care during times when study coordinators are available and/or who respond to telephone calls from study coordinators after their visit.

Ethics and dissemination
Each site has obtained local institutional review board (IRB) approval; the IRBs approving the study are: Cedars-Sinai’s Institutional Review Board, Mayo Clinic Institutional Review Board, Yale University Institutional Review Board, University of Alabama-Birmingham Institutional Review Board for Human Use, and Monument Health Institutional Review Board.

Study results will be disseminated through publications in general and specialty medical journals and conferences.

Study update
As of this writing, all sites have obtained local IRB approval and are enrolling participants. COVID-19 has severely impacted study enrollment at nearly all sites. Several sites were not allowed to recruit in person for some period of the pandemic. The effect of the pandemic and associated changes in healthcare service use on the results of the study are not yet known and will be an important aspect in analysis of the study results.

Based on priority conditions identified by the National Academies of Sciences, Engineering and Medicine acute pain prescribing working group,26 two study sites were given permission to recruit limited numbers of people receiving hip or knee replacement surgery and people who recently gave birth.

Author affiliations
1Emergency Medicine and Health Care Delivery Research, Mayo Clinic, Rochester, Minnesota, USA
2Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland, USA
3Knowledge and Evaluation Research Unit; Department of Family Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA
4Office of the Commissioner, Office of Minority Health and Health Equity, US Food and Drug Administration, Silver Spring, Maryland, USA
5Center for Drug Evaluation and Research, Office of Translational Sciences, US Food and Drug Administration, Silver Spring, Maryland, USA
6Division of Population Health and Genomics, University of Dundee School of Medicine, Dundee, UK
7Division of Health Care Delivery Research, Kern Center for the Science of Health Care Delivery, Mayo Clinic Rochester, Rochester, Minnesota, USA
8Department of Surgery, Mayo Clinic Division of Oral and Maxillofacial Surgery, Rochester, Minnesota, USA
9Department of Clinical and Community Sciences, School of Dentistry, The University of Alabama at Birmingham School of Dentistry, Birmingham, Alabama, USA
10Department of Obstetrics, Gynecology, & Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, USA
11Center for Drug Evaluation and Research, Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland, USA
12Division of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
13Department of Emergency Medicine, Department of Medicine, Division of Pulmonary, Allergy & Critical Care Medicine, The University of Alabama, Birmingham, Alabama, USA
14Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
15Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Center for Outcomes Research and Evaluation, Yale University Center for Outcomes Research and Evaluation, New Haven, Connecticut, USA

Internal Medicine, Yale University Center for Outcomes Research and Evaluation, New Haven, Connecticut, USA

Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA

Department of Family Medicine, Monument Health, Rapid City, South Dakota, USA

Department of Emergency Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA

Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA

Twitter Molly Moore Jeffery @mollyjeffery and Fernanda Bellolio @mbellolio

Acknowledgements Dr. Nilay Shah is currently an employee at Delta Airlines, while Dr. Elektra Papadopoulos is currently an employee at AbbVie. During the time when they were actively engaged and collaborating on this study, they were affiliated with the Mayo Clinic and FDA, respectively.

Contributors Conception or design of the work: MMJ, NDS, JSR, JDR, MA, NC. Planning for acquisition, analysis, or interpretation of data: MA, RA, NC, PK, CL, CM, MM, MAP, EP, MS, COSC, YZ, SA, FB, JF, GHG, HL, TN, DBP, STA, STO, DW, MMJ, LC, LE, JDR, JSR, NDS. RH Drafting the work: MMJ, RH Revising the work critically for important intellectual content: MA, RA, NC, PK, CL, CM, TM, MM, MAP, EP, MS, COSC, YZ, SA, FB, JF, GHG, HL, TN, DBP, STA, STO, DW, MMJ, LC, LE, JDR, JSR, NDS, RH Final approval of the version to be published: MA, RA, NC, PK, CL, CM, MM, MAP, EP, MS, COSC, YZ, SA, FB, JF, GHG, HL, TN, DBP, STA, STO, DW, MMJ, LC, LE, JDR, JSR, NDS. RH Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: MMJ.

Funding This publication is supported by the Food and Drug Administration (FDA) of the US Department of Health and Human Services (HHS) as part of a financial assistance award (Center of Excellence in Regulatory Science and Innovation grant to Yale University and Mayo Clinic, U01FD005938) totaling US$6 119 692 with 100% funded by FDA/HHS.

Disclaimer The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the US Government.

Map disclaimer The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

Competing interests In the past three years, Dr. Jeffery has received unrelated grant funding from the Agency for Healthcare Research and Quality, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the American Cancer Society and the US Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Dr. Ross currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS22882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from the Laura and John Arnold Foundation to establish the Good Pharmas Scorecard at Bioethics International; in addition, Dr. Ross is an expert witness at the request of Relator’s attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. Ms. Ritchie currently receives research support through Yale University from Johnson & Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), and from the US Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Ms. Emanuel received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST) and from the US Food and Drug Administration for the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Dr. Gilbert currently receives research support from the National Institutes of Health (U19DE228717). Dr. Bellolio received funding from the National Center for Complementary and Integrative Health, the National Institute on Aging, and Diagnostic Robotics. Dr. Heckmann reported receiving salary support from CMS to develop, implement, and maintain hospital performance outcome measures that are publicly reported, in addition to receiving research support through Yale as part of a Centers for Disease Control and Prevention project designed to strengthen prescription drug overdose prevention efforts, from Connecticut Department of Public Health as part of a public health project designed to assess the impact of Good Samaritan Laws, and from the Community Health Network of Connecticut for her work as a medical consultant. Dr Lipkind serves on the Pfizer independent external data monitoring committee for the COVID-19 vaccine. Since leaving the Yale-New Haven Center for Outcomes Research and Evaluation, Ms. Ciacio has been employed part-time at Hugh Health.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Molly Moore Jeffery http://orcid.org/0000-0003-3854-6810 Fernanda Bellolio http://orcid.org/0000-0002-1632-4750

REFERENCES


16 Mundkur ML, Franklin JM, Abdia Y, et al. Days’ supply of initial opioid analgesic prescriptions and additional fills for acute pain conditions.